Drug Information

Drug General Information
Drug ID
D0K9NW
Former ID
DNC012625
Drug Name
4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline
Drug Type
Small molecular drug
Indication Discovery agent Investigative [526618]
Formula
C18H16N2
Canonical SMILES
C1CN(CC2=CC=CC=C21)C3=CC=NC4=CC=CC=C43
InChI
1S/C18H16N2/c1-2-6-15-13-20(12-10-14(15)5-1)18-9-11-19-17-8-4-3-7-16(17)18/h1-9,11H,10,12-13H2
InChIKey
HRDFYQVITWAQGZ-UHFFFAOYSA-N
PubChem Compound ID
18326767
Target and Pathway
Target(s) Alpha-1B adrenergic receptor Target Info Inhibitor [526618]
Alpha-1D adrenergic receptor Target Info Inhibitor [526618]
NMDA receptor subunit NR1 Target Info Inhibitor [526618]
Glutamate [NMDA] receptor subunit epsilon 2 Target Info Inhibitor [526618]
Alpha-1A adrenergic receptor Target Info Inhibitor [526618]
KEGG Pathway Calcium signaling pathway
cGMP-PKG signaling pathway
Neuroactive ligand-receptor interaction
Adrenergic signaling in cardiomyocytes
Vascular smooth muscle contraction
Salivary secretionhsa04020:Calcium signaling pathway
Salivary secretionhsa04014:Ras signaling pathway
Rap1 signaling pathway
cAMP signaling pathway
Circadian entrainment
Long-term potentiation
Glutamatergic synapse
Alzheimer's disease
Amyotrophic lateral sclerosis (ALS)
Huntington's disease
Cocaine addiction
Amphetamine addiction
Nicotine addiction
Alcoholismhsa04014:Ras signaling pathway
Dopaminergic synapse
Alcoholism
Systemic lupus erythematosushsa04020:Calcium signaling pathway
AMPK signaling pathway
Salivary secretion
NetPath Pathway IL2 Signaling PathwayNetPath_14:IL2 Signaling Pathway
PANTHER Pathway Alpha adrenergic receptor signaling pathwayP00029:Huntington disease
Ionotropic glutamate receptor pathway
Metabotropic glutamate receptor group III pathway
Metabotropic glutamate receptor group I pathway
Muscarinic acetylcholine receptor 1 and 3 signaling pathwayP00029:Huntington disease
Muscarinic acetylcholine receptor 1 and 3 signaling pathwayP00002:Alpha adrenergic receptor signaling pathway
Pathway Interaction Database LPA receptor mediated eventserbb4_pathway:ErbB4 signaling events
Reelin signaling pathway
Reactome Adrenoceptors
G alpha (q) signalling events
G alpha (12/13) signalling eventsR-HSA-390696:Adrenoceptors
G alpha (12/13) signalling eventsR-HSA-3928662:EPHB-mediated forward signaling
Unblocking of NMDA receptor, glutamate binding and activation
CREB phosphorylation through the activation of CaMKII
Ras activation uopn Ca2+ infux through NMDA receptor
RAF/MAP kinase cascadeR-HSA-3928662:EPHB-mediated forward signaling
RAF/MAP kinase cascadeR-HSA-390696:Adrenoceptors
G alpha (12/13) signalling events
WikiPathways Monoamine GPCRs
Calcium Regulation in the Cardiac Cell
GPCRs, Class A Rhodopsin-like
Vitamin D Receptor Pathway
Gastrin-CREB signalling pathway via PKC and MAPK
GPCR ligand binding
GPCR downstream signaling
AMPK SignalingWP58:Monoamine GPCRs
GPCRs, OtherWP706:SIDS Susceptibility Pathways
Hypothetical Network for Drug Addiction
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
Spinal Cord Injury
BDNF signaling pathway
Alzheimers DiseaseWP666:Hypothetical Network for Drug Addiction
BDNF signaling pathwayWP58:Monoamine GPCRs
Endothelin Pathways
AMPK Signaling
References
Ref 526618Bioorg Med Chem Lett. 2003 May 19;13(10):1759-62.4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor antagonists.
Ref 526618Bioorg Med Chem Lett. 2003 May 19;13(10):1759-62.4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor antagonists.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.